Source: shutterstock.com
  • Treatment.com International Inc. (TRUE) has collaborated with the University of Minnesota (U of M) Medical School to test its innovative healthcare AI
  • U of M Medical School’s faculty will do “rigorous” testing Treatment’s AI engine named MERLIN and evaluate its ability to improve and assist the healthcare assessments of third- and fourth-year students
  • Dr. Kevin A. Peterson, Chief Medical Officer of Treatment, said by working with the medical students the company can test its AI against textbook medical school cases
  • In addition to MERLIN, a mobile app for health assessment, Cara, will leverage the same AI engine tested by U of M Medical School, and is set to launch this year
  • Treatment.com International Inc. (TRUE) is unchanged trading at $2.10 per share at 11:30 a.m. ET

Treatment.com International (TRUE) has collaborated with the University of Minnesota (U of M) Medical School to test its innovative healthcare AI.

U of M Medical School’s faculty will do “rigorous” testing Treatment’s AI engine named MERLIN and evaluate its ability to improve and assist the healthcare assessments of third- and fourth-year students.

The testing will evaluate MERLIN’s ability to identify the most common diseases based on a patient’s presentation of symptoms.

Dr. Kevin A. Peterson, Chief Medical Officer of Treatment, said by working with the medical students the company can test its AI against textbook medical school cases.

“The students also have the opportunity to challenge their knowledge against the AI engine, furthering their understanding of primary care diagnostic assessments and providing an opportunity to support doctors in making better clinical evaluations in the future,” he said.

In addition to MERLIN, a mobile app for health assessment, Cara, will leverage the same AI engine tested by U of M Medical School and is set to launch this year.

“So much of primary care can be captured in the top 500 diseases. When we can confidently assess and treat those conditions, the health of the entire population stands to improve… our AI platform improves even more and offers us additional opportunities to use our technology with doctors in real medical clinics and environments,” said Dr. Peterson.

Treatment.com International Inc. (TRUE) is unchanged trading at $2.10 per share at 11:30 a.m. ET.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.